Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2023, with a specific reporting date of October 12, 2023. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of share transactions.
| Instrument | Transaction Type | Transaction Date | Price per Share | Total Volume |
|---|---|---|---|---|
| Ordinary Shares (31 1/2 pence each) | Acquisition under Share Reward Plan | 2023-10-10 | £15.2208 | 142 Shares |
Note: The total volume of 142 shares is an aggregate of 8 PDMRs and 1 PCA, each acquiring between 16 and 18 shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It discloses routine equity compensation acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed on the London Stock Exchange (XLON) and represent standard participation in the company's equity incentive program.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the GSK Share Reward Plan, not open market sales or purchases.
- Participants: Transactions involved 9 individuals, including CEO Emma Walmsley, CFO Julie Brown, and other senior executives.
- Valuation: All shares were acquired at a uniform price of £15.2208 per share on October 10, 2023.
- Scope: This document does not provide quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance data.